- Anglada-Girotto, Miquel
- Segura-Morales, Carolina
- Moakley, Daniel F.
- Zhang, Chaolin
- Miravet Verde, Samuel, 1992-
- Califano, Andrea
- Serrano Sánchez, Antonio L.
Splicing factors control exon inclusion in messenger RNAs, shaping transcriptome and proteome diversity. Their catalytic activity is regulated by multiple layers, making single-omic measurements on their own fall short in identifying which splicing factors underlie a phenotype. Here, we posit that splicing factor activity, defined as a splicing factor's ability to modulate exon inclusion, can be estimated from changes in exon inclusion signatures. To test this hypothesis, we benchmark methods for constructing splicing factor-exon networks and estimating splicing factor activity. We find that combining RNA-seq perturbation-based networks with VIPER (Virtual Inference of Protein Activity by Enriched Regulon analysis) accurately captures splicing factor activity as modulated by multiple regulatory layers. This approach integrates splicing factor regulation into a single score derived solely from exon inclusion signatures, allowing functional interpretation of heterogeneous conditions. As a proof of concept, we identify recurrent cancer splicing programs, revealing associations with oncogenic- and tumor suppressor-like splicing factors missed by conventional methods. These programs correlate with patient survival and key cancer hallmarks: initiation, proliferation, and immune evasion. Altogether, we show splicing factor activity can be accurately estimated from exon inclusion changes, enabling comprehensive analyses of splicing regulation with minimal data requirements., We thank William C. Hahn, Annica Gad, Emma Lundberg, and Staffan Strömblad for kindly sharing the BJ fibroblasts and its derivatives with us. And, Attila Biçer and Matilde D'Angelo for their help in culturing BJ fibroblast cell lines. We would like to thank Luca Zanella, Lucas ZhongMing Hu, Alessandro Vasciaveo, Alec Wang for their support in the reimplementation of VIPER. We would like to thank Sophie Bonnal, Malgorzata Ewa Rogalska, Juan Valcárcel, Manuel Irimia, Yamile Ana, Javier Gonzalez-de-Miguel and Xavier Hernandez-Alias for the insightful discussions regarding the elucidation of splicing factor programs. Also, we would like to thank Hector C Keun, Clare Eckold and Anke Nijhuis for kindly sharing proteomics sample metadata and raw RNA sequencing data from cells treated with indisulam. We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme, and to the EMBL partnership. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. The proteomics analyses were performed in the CRG/UPF Proteomics Unit, which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). The results shown here are in part based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga). This project was funded by grants from the Plan Estatal de Investigación Científica y Técnica y de Innovación to LS (PID2021-122341NB-I00 project funded MICIU / AEI / 10.13039 / 501100011033 / FEDER, UE). Further, the project was also supported by the NCI U54CA274506 (Center for Cancer Systems Therapeutics, CaST), the NCI Outstanding Investigator Award R35 CA197745, and the NIH Shared Instrumentation Grants S10 0D012351 and S10 OD021764 and S10 0D032433 all to AC. In addition, CZ was supported by grants from NIH (R01NS125018 and R35GM145279). And, MA-G was supported in part by a Boehringer Ingelheim Fonds travel grant.